Skip to content

Pharmaceutical Crystallization Summit

Breaking Drug Development Bottlenecks via Enabling Technologies

October 14-15, 2021

  • Home
  • Program
    • Program for Live Attendance
    • Program for Virtual Attendance
  • Abstracts
    • Session 1: Smarter Solid Form & Pre-formulation Studies
    • Session 2: Particle Engineering & DS-DP Co-Processing
    • Session 3: Physical Property Based Crystallization Process Development
  • Keynote Speakers & Moderators
  • Venue
    • Chauncey Hotel & Conference Center
    • COVID-19 Safety Protocols
    • Destination Guide
  • Partners
    • Center for Pharma Crystallization
    • J-STAR Research, Inc.
    • Porton Pharma Solutions Ltd.
    • XtalPi
    • BlazeMetrics
    • Technobis Crystallization Systems
  • COVID-19 Prevention
    • Chauncey’s Health & Safety Plan
    • PCS COVID-19 Prevention

Session 4: Topical Panel Discussions

Potentials and Technologies to Increase Success Rate of Polymorph Screening

By admin

Moderator: Dr. Alfred Lee, Merck

Read More

Overcoming Industrial Challenges in Implementation of Crystallization Technologies

By admin

Moderator: Dr. Kevin Girard, Pfizer

Read More

Realizing Regulatory Challenges in Applying Crystallization Technologies

By admin

Moderator: Dr. Christopher Burcham, Eli Lilly and Company

Read More

Session 1: Smarter Solid Form & Pre-formulation Studies

  • Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264): A Solid-State Chemistry Perspective
    Dr. Alfred Lee, Merck Research Laboratories
  • What Solid Form Should I Choose?
    Ann Newman, Seventh Street Development Group
  • Understanding and Controlling the API Form/Powder Property Risks in Drug Substance and Product Processes
    Dr. Shawn Yin, Bristol Myers Squibb
  • Absolute Structure Determination of API Molecules by MicroED analysis of Cocrystals formed based on Cocrystal Propensity Prediction Calculations
    Drs. Chandler Greenwell (XtalPi), Harsh Shah (J-Star), and Jessica Bruhn (NIS)

Session 2: Particle Engineering & DS-DP Co-Processing

  • Examples of Particle Engineering to Improve Patient Outcomes and Product Manufacturing
    Dr. Christopher Burcham, Eli Lilly and Company
  • Crystal Habit Modifications and Spherical Crystallization Design in Solution
    Prof. Junbo Gong, Tianjin University
  • Challenges and Opportunities in Optimizing Mechanical Properties of Drugs by Incorporating Excipients
    Prof. Calvin Changquan Sun, University of Minnesota
  • Bridging the Gap between Drug Substance and Drug Product Processing via Co-Processing
    Dr. Jian Wang, CfPC/J-Star/Porton

Session 3: Physical Property Based Crystallization Process Development

  • The Importance of Understanding and Characterising the Physical & Chemical Properties of APIs in the Digital Design of Drug Products
    Prof. Kevin Roberts, University of Leeds
  • Continuous Crystallization and Purification: The Role of Impurity Incorporation Mechanism in Non-Equilibrium Processes
    Prof. Allan Myerson, MIT
  • Co-Crystals Platform to Improve Physical Properties of Early Intermediates during API Manufacturing Process
    Dr. Samir Kulkarni, Pfizer
  • Correlation of Solubility with the Metastable Limit
    Prof. Ken Morris, Long Island University

Session 4: Topical Panel Discussions

  • Potentials and Technologies to Increase Success Rate of Polymorph Screening
    Moderator: Dr. Alfred Lee, Merck
  • Overcoming Industrial Challenges in Implementation of Crystallization Technologies
    Moderator: Dr. Kevin Girard, Pfizer
  • Realizing Regulatory Challenges in Applying Crystallization Technologies
    Moderator: Dr. Christopher Burcham, Eli Lilly and Company

© 2021 Pharmaceutical Crystallization Summit. All Rights Reserved.

Scroll To Top